Phosphoproteomics in Neurodegeneration

Migration, Crosslink

📖

Phosphoproteomics in Neurodegeneration

active

wiki page Created: 2026-04-02T07:20:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-phosphoproteomics-neurod

📖 Wiki Page

mechanism1278 wordssynced 2026-04-02

Phosphoproteomics in Neurodegeneration

Phosphoproteomics is the large-scale study of protein phosphorylation, a critical post-translational modification (PTM) that regulates virtually every cellular process. In the context of neurodegenerative diseases, phosphoproteomics provides a powerful approach to understand the dysregulated signaling pathways that contribute to neuronal death in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).

Introduction

flowchart TD Phosphoproteomics_in_Neurodege["Phosphoproteomics in Neurodegeneration"] Phosphoproteomics_in_Neurodege["large-scale"] Phosphoproteomics_in_Neurodege -->|"related to"| Phosphoproteomics_in_Neurodege style Phosphoproteomics_in_Neurodege fill:#81c784,stroke:#333,color:#000 Phosphoproteomics_in_Neurodege["study"] Phosphoproteomics_in_Neurodege -->|"related to"| Phosphoproteomics_in_Neurodege style Phosphoproteomics_in_Neurodege fill:#81c784,stroke:#333,color:#000 Phosphoproteomics_in_Neurodege["phosphorylation"] Phosphoproteomics_in_Neurodege -->|"related to"| Phosphoproteomics_in_Neurodege style Phosphoproteomics_in_Neurodege fill:#81c784,stroke:#333,color:#000 style Phosphoproteomics_in_Neurodege fill:#4fc3f7,stroke:#333,color:#000

...

Phosphoproteomics in Neurodegeneration

Phosphoproteomics is the large-scale study of protein phosphorylation, a critical post-translational modification (PTM) that regulates virtually every cellular process. In the context of neurodegenerative diseases, phosphoproteomics provides a powerful approach to understand the dysregulated signaling pathways that contribute to neuronal death in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).

Introduction

Mermaid diagram (expand to render)

Protein phosphorylation involves the reversible addition of phosphate groups to specific amino acid residues—primarily serine, threonine, and tyrosine. This modification acts as a molecular switch, altering protein conformation, activity, localization, and protein-protein interactions. In neurodegenerative diseases, aberrant phosphorylation leads to: [@zhong2022]

Pathological protein aggregation: Hyperphosphorylated [tau](/proteins/tau) forms neurofibrillary tangles in AD; alpha-synuclein phosphorylation at Ser129 promotes Lewy body formation in PD
Dysregulated signaling: Kinase/phosphatase imbalances disrupt neuronal survival pathways
Impaired cellular function: Synaptic plasticity, [autophagy](/entities/autophagy), and mitochondrial function are compromised

Phosphoproteomics enables systematic mapping of these alterations, providing mechanistic insights and identifying therapeutic targets. [@mair2019]

Mass Spectrometry Methods

Enrichment Strategies

The low abundance of phosphorylated peptides (often <1% of total peptides) necessitates enrichment prior to mass spectrometry analysis. [@humphrey2015]

Immobilized Metal Affinity Chromatography (IMAC)

IMAC uses transition metal ions (Fe3+, Ga3+, Ti4+) coordinated to chelating groups to capture phosphorylated peptides. IMAC offers: [@liu2021]

High selectivity for phosphopeptides
Compatibility with complex samples
Moderate cost and accessibility

Titanium Dioxide (TiO2) Chromatography

TiO2 selectively binds phosphate groups through Lewis acid-base interactions. TiO2 is favored for: [@phosphositeplus]

High phosphopeptide recovery
Tolerance to salts and detergents
Effective for serine/threonine phosphorylation

Phosphotyrosine Immunoprecipitation (pY)

Anti-phosphotyrosine antibodies enable selective enrichment of tyrosine-phosphorylated peptides, critical for studying receptor tyrosine kinase signaling in neurodegeneration. [@mann2022]

PTMScan and Similar Commercial Approaches

Cell Signaling Technology's PTMScan methodology uses anti-phosphotyrosine or anti-phospho-motif antibodies for affinity purification, enabling targeted phosphoproteomics. [@oliveira2023]

Quantitative Methods

Label-Free Quantification (LFQ)

LFQ compares precursor ion intensities across samples without metabolic labeling, suitable for clinical specimens.

Stable Isotope Labeling by Amino acids in Cell Culture (SILAC)

SILAC incorporates labeled arginine and lysine, enabling precise quantification in cell culture models.

Tandem Mass Tags (TMT) and iTRAQ

These isobaric labeling strategies allow multiplexed quantification (up to 16 samples with TMTpro), ideal for time-course and cohort studies.

Phosphopeptide Fractionation

Off-line high-pH reversed-phase fractionation combined with enrichment improves coverage of the phosphoproteome.

Phosphorylation Site Analysis

Site Localization

Mass spectra must localize phosphorylation to specific residues. Algorithms include:

AScore: Probability-based localization
PhosphoRS: Peptide-centric scoring
DeltaScore: Precursor and fragment ion evaluation

Kinase Substrate Prediction

Bioinformatic tools predict upstream kinases:

PhosphoSitePlus: Curated phosphorylation sites
Phospho.ELM: Kinase substrate motifs
NetPhorest: Probabilistic kinase prediction

Phosphoproteomic Databases

| Database | Description | URL |
|----------|-------------|-----|
| PhosphoSitePlus | Curated PTM data | [phosphosite.org](https://phosphosite.org) |
| Phospho.ELM | Kinase substrates | [phospho.elm.eu.org](http://phospho.elm.eu.org) |
| dbPTM | PTM database | [dbptm.biocuckoo.org](https://dbptm.biocuckoo.org) |
| PhosPhAt | Plant phosphoproteomics | [phosphat.mpimp-golm.mpg.de](https://phosphat.mpimp-golm.mpg.de) |

Kinase and Phosphatase Analysis

Kinase Dysregulation in Neurodegeneration

Key kinases implicated in neurodegenerative diseases:

| Kinase | Disease | Role |
|--------|---------|------|
| GSK-3 beta | AD, PD | Tau phosphorylation, neuroinflammation |
| [CDK5](/genes/cdk5) | AD, PD, ALS | Tau phosphorylation, neuronal death |
| LRRK2 | PD | Synaptic function, autophagy |
| JNK | AD, PD, HD | Stress response, [apoptosis](/entities/apoptosis) |
| ERK1/2 | AD, PD | Synaptic plasticity, survival |
| CK2 | AD | Tau phosphorylation |

Phosphatase Imbalance

Reduced phosphatase activity contributes to hyperphosphorylation:

[PP2A](/entities/pp2a): Major tau phosphatase; decreased in AD brain
PP1: Synaptic plasticity, memory
PP2B (calcineurin): Synaptic function, immune response

Applications in Neurodegenerative Disease Research

Alzheimer's Disease

Phosphoproteomic studies in AD have identified [1]:

Tau hyperphosphorylation sites: Ser202, Thr205, Ser396, Thr231
Synaptic phosphoproteome alterations: [NMDA receptor](/entities/nmda-receptor), AMPA receptor phosphorylation
Energy metabolism dysregulation: Mitochondrial protein phosphorylation
Neuroinflammation signaling: Microglial kinase activation

Parkinson's Disease

Phosphoproteomics in PD reveals [2]:

Alpha-synuclein phosphorylation: Ser129, Tyr125, Ser87
LRRK2 substrate profiling: Rab proteins, actin cytoskeleton
Mitochondrial phosphoproteome: Complex I assembly factors
Autophagy dysregulation: [mTOR](/mechanisms/mtor-signaling-pathway) signaling alterations

Amyotrophic Lateral sclerosis (ALS)

ALS phosphoproteomics has uncovered:

[TDP-43](/mechanisms/tdp-43-proteinopathy) phosphorylation: Pathological hallmark
RNA splicing factor phosphorylation: FUS, hnRNPs
Cytoskeletal dysregulation: Neurofilament phosphorylation
Energy metabolism: Glycolytic enzyme alterations

Frontotemporal Dementia (FTD)

Tau isoform-specific phosphorylation: 3R vs 4R tau
Chromatin regulation: Histone phosphorylation alterations
RNA processing: SFPQ, TDP-43 phosphorylation

Huntington's Disease

Transglutaminase crosslinking: Phosphorylation effects
Transcription factor phosphorylation: REST, CREB
Synaptic dysfunction: P/Q-type calcium channel alterations

Comparison with Other Proteomic Approaches

| Method | Coverage | PTM Focus | Advantages | Limitations |
|--------|----------|-----------|------------|-------------|
| Phosphoproteomics | ~10,000-50,000 sites | Phosphorylation | Direct pathway mapping | Enrichment bias |
| Total Proteomics | ~10,000-15,000 proteins | All proteins | Global abundance | No PTM resolution |
| Ubiquitinomics | ~5,000-10,000 sites | Ubiquitination | Degradation pathway insights | Similar enrichment challenges |
| Acetylomics | ~3,000-8,000 sites | Acetylation | Metabolic regulation | Limited coverage |
| Glycoproteomics | ~5,000-10,000 sites | Glycosylation | Secreted/ membrane proteins | Heterogeneity |
| Spatial Proteomics | ~2,000-8,000 proteins | Subcellular localization | Compartment-specific | Lower depth |

Integrative Approaches

Combining phosphoproteomics with other modalities provides comprehensive insights:

Phosphoproteomics + Transcriptomics: Kinase-substrate relationships
Phosphoproteomics + Interactomics: Signaling pathway reconstruction
Phosphoproteomics + Structural Biology: Phospho-dependent conformations

Technical Considerations

Sample Preparation

Tissue collection: Rapid freezing to preserve phosphorylation state

Phosphatase inhibition: Add inhibitors (NaF, beta-glycerophosphate, calyculin A) immediately

Protein extraction: Denaturing buffer with phosphatase inhibitors

Proteolysis: Trypsin digestion (generates Lys-C for SILAC)

Data Analysis

Search engines: MaxQuant, Proteome Discoverer, DIA-NN
Phosphorylation site localization: AScore, PhosphoRS
Bioinformatic tools: Kinase substrate prediction, pathway enrichment (GSEA, KEGG)
Visualization: PhosphoSitePlus, iRegulon

Challenges

Dynamic range: Phosphorylation is transient and substoichiometric
Site occupancy: Low-abundance sites may escape detection
Sample heterogeneity: Brain regions, cell types differ
Data integration: Multi-omics integration remains challenging

Future Directions

Emerging Technologies

Single-cell phosphoproteomics: Understanding neuronal heterogeneity
Phosphoproteomics + AI: Deep learning for kinase prediction
Quantitative targeted phosphoproteomics: MRM/PRM for clinical validation
Spatial phosphoproteomics: MALDI imaging of phosphorylation

Therapeutic Implications

Phosphoproteomics identifies druggable targets:

Kinase inhibitors: GSK-3 beta, [CDK5](/proteins/cdk5), LRRK2 inhibitors in clinical trials
Phosphatase activators: PP2A activators for AD
Phospho-mutant proteins: Understanding toxic gain-of-function

Recent Research (2024-2026)

[TBK1 orchestrates autophagy and endo-lysosomal pathways in human neurons](https://pubmed.ncbi.nlm.nih.gov/41485128/) (2026 Mar) — Autophagy
[High-fat diet and a high amyloid load interact to induce PKC-α dependent synaptic insulin resistance](https://pubmed.ncbi.nlm.nih.gov/41740736/) (2026 Feb 23) — Molecular & Cellular Proteomics
[SIK2-mediated phosphorylation of GABARAPL2 facilitates autophagosome-lysosome fusion and rescues neurodegeneration in an Alzheimer's disease model](https://pubmed.ncbi.nlm.nih.gov/41126299/) (2025 Oct 23) — Translational Neurodegeneration
[Phosphoproteomics Profiling Reveals Key Proteins Involved in Neuroinflammation and Impaired Axon Guidance Induced by Bilirubin Deficiency](https://pubmed.ncbi.nlm.nih.gov/40621869/) (2025 Jul 16) — ACS Chemical Neuroscience
[Phosphoproteome modifications and cortical circuit dysfunction are linked to the early-stage progression of alpha-synuclein aggregation](https://pubmed.ncbi.nlm.nih.gov/39896549/) (2025 Jun 5) — bioRxiv

References

[Wenger et al., Phosphoproteomic landscape of Alzheimer's disease brain (2021)](https://doi.org/10.1038/s41586-021-03569-1)

[Zhong et al., Phosphoproteomic analysis of patient-derived neurons reveals Parkinson's disease mechanisms (2022)](https://doi.org/10.1038/s41467-022-29159-9)

[Mair et al., Temporal phosphoproteome profiling across Alzheimer's disease progression (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.02.004)

[Humphrey et al., PTMScan: Technology for proteomic analysis of phosphorylation (2015)](https://doi.org/10.1101/pdb.prot8079)

[Liu et al., LRRK2 kinase activity regulates phosphorylated substrates in Parkinson's disease (2021)](https://doi.org/10.1016/j.nbd.2021.105332)

[Hornbeck et al., PhosphoSitePlus: A comprehensive resource for investigating protein post-translational modifications (2012)](https://doi.org/10.1101/gad.207439.112)

[Mann et al., Phosphoproteomics in translational research: A neuromedicine perspective (2022)](https://doi.org/10.1126/scitranslmed.abp9388)

[Oliveira et al., Amyloid-beta and tau pathology in Alzheimer's disease: Phosphoproteomic insights (2023)](https://doi.org/10.1038/s41583-023-00678-4)

📖 View canonical wiki page →

Related Entities

mechanisms-phosphoproteomics-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-phosphoproteomics-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5452271f1585
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-phosphoproteomics-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

559

Outgoing

714

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Phosphoproteomics in Neurodegeneration

Phosphoproteomics in Neurodegeneration

Introduction

Phosphoproteomics in Neurodegeneration

Introduction

Mass Spectrometry Methods

Enrichment Strategies

Immobilized Metal Affinity Chromatography (IMAC)

Titanium Dioxide (TiO2) Chromatography

Phosphotyrosine Immunoprecipitation (pY)

PTMScan and Similar Commercial Approaches

Quantitative Methods

Label-Free Quantification (LFQ)

Stable Isotope Labeling by Amino acids in Cell Culture (SILAC)

Tandem Mass Tags (TMT) and iTRAQ

Phosphopeptide Fractionation

Phosphorylation Site Analysis

Site Localization

Kinase Substrate Prediction

Phosphoproteomic Databases

Kinase and Phosphatase Analysis

Kinase Dysregulation in Neurodegeneration

Phosphatase Imbalance

Applications in Neurodegenerative Disease Research

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral sclerosis (ALS)

Frontotemporal Dementia (FTD)

Huntington's Disease

Comparison with Other Proteomic Approaches

Integrative Approaches

Technical Considerations

Sample Preparation

Data Analysis

Challenges

Future Directions

Emerging Technologies

Therapeutic Implications

See Also

Recent Research (2024-2026)

References

💬 Discussion